Literature DB >> 30287281

Bispecific applications of non-immunoglobulin scaffold binders.

Sophia Hober1, Sarah Lindbo1, Johan Nilvebrant2.   

Abstract

Non-immunoglobulin scaffolds represent a proven group of small affinity proteins that can be engineered in vitro to similar affinity and potency as monoclonal antibodies. Several novel candidate biotherapeutics that exploit the potential advantages scaffold proteins hold over larger and more complex antibodies have been developed over the past decade. The ease of using small and robust binding proteins as flexible and modular building blocks has led to the development of a wide range of innovative approaches to combine them in various bi- and multispecific formats. This progress is expected to aid the ongoing challenge of identifying niche applications where clear differentiation from antibody-based molecules will be key to success. Given the many engineering options that are available for non-immunoglobulin scaffold proteins, they have potential to not only complement but probably also surpass antibodies in certain applications.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords:  Biparatopic; Bispecific; In vitro evolution; Non-immunoglobulin scaffold; Protein engineering

Mesh:

Year:  2018        PMID: 30287281     DOI: 10.1016/j.ymeth.2018.09.010

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  6 in total

Review 1.  Beyond Antibodies: The DARPin® Drug Platform.

Authors:  Michael T Stumpp; Keith M Dawson; H Kaspar Binz
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

2.  Engineering mono- and multi-valent inhibitors on a modular scaffold.

Authors:  Aurora Diamante; Piyush K Chaturbedy; Pamela J E Rowling; Janet R Kumita; Rohan S Eapen; Stephen H McLaughlin; Marc de la Roche; Albert Perez-Riba; Laura S Itzhaki
Journal:  Chem Sci       Date:  2020-12-17       Impact factor: 9.969

3.  Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting.

Authors:  Erwin Pannecoucke; Maaike Van Trimpont; Johan Desmet; Tim Pieters; Lindy Reunes; Lisa Demoen; Marnik Vuylsteke; Stefan Loverix; Karen Vandenbroucke; Philippe Alard; Paula Henderikx; Sabrina Deroo; Franky Baatz; Eric Lorent; Sophie Thiolloy; Klaartje Somers; Yvonne McGrath; Pieter Van Vlierberghe; Ignace Lasters; Savvas N Savvides
Journal:  Sci Adv       Date:  2021-03-26       Impact factor: 14.136

Review 4.  Emerging new therapeutic antibody derivatives for cancer treatment.

Authors:  Shijie Jin; Yanping Sun; Xiao Liang; Xinyu Gu; Jiangtao Ning; Yingchun Xu; Shuqing Chen; Liqiang Pan
Journal:  Signal Transduct Target Ther       Date:  2022-02-07

5.  A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.

Authors:  Michelle K Becker-Hapak; Niraj Shrestha; Ethan McClain; Michael J Dee; Pallavi Chaturvedi; Gilles M Leclerc; Lynne I Marsala; Mark Foster; Timothy Schappe; Jennifer Tran; Sweta Desai; Carly C Neal; Patrick Pence; Pamela Wong; Julia A Wagner; David A Russler-Germain; Xiaoyun Zhu; Catherine M Spanoudis; Victor L Gallo; Christian A Echeverri; Laritza L Ramirez; Lijing You; Jack O Egan; Peter R Rhode; Jin-An Jiao; Gabriela J Muniz; Emily K Jeng; Caitlin A Prendes; Ryan P Sullivan; Melissa M Berrien-Elliott; Hing C Wong; Todd A Fehniger
Journal:  Cancer Immunol Res       Date:  2021-07-09       Impact factor: 11.151

Review 6.  Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain.

Authors:  Peter G Chandler; Ashley M Buckle
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.